Award Data

DESCRIPTION (provided by applicant): Cardiac failure is the, largest single cause of mortality in the United States today. With an increase in the use of long-term cardiac assist devices, there is also a need for the short-term "bridge to recovery" application. This application is intended to provide a low-cost temporary support for patients whose heart is capable of recovering. This "patient scr ...

DESCRIPTION (provided by applicant): Currently almost half of all trauma mortality is directly or indirectly attributable to hemorrhagic shock, accounting for more than 50,000 deaths yearly in the U.S. and hundreds of billions of dollars in economic costs. Active Signal Technologies proposes to develop an Acoustic Resuscitation Monitor (ARM) for enabling non-invasive assessment of systemic perfusi ...

DESCRIPTION (provided by applicant) The primary aim is to facilitate the development and delivery of live, interactive HAZWOPER training through the use of internet-based Advanced Training Technologies (ATT). To this end, ATL has designed the ATL Web-based Training Center as a fully integrated portal that provides synchronous and asynchronous training from one access point for all students and ...

DESCRIPTION (provided by applicant): Wet age-related macular degeneration (AMD) is the leading cause of blindness in the developed world and represents a disease with a great unmet medical need. The blindness associated with wet AMD is caused by neovascularization and treatments are aimed at inhibiting this progress. The Advanced Vision Therapies, Inc. (AVT) strategy is to combine its gene deliver ...

DESCRIPTION: Advanced Vision Therapies, Inc. (AVT) is developing novel therapies for ocular disorders that are the major causes of blindness in the developed world. The initial indications are the neovascular diseases, wet age-related macular degeneration and diabetic proliferative retinopathy. Disease pathophysiology is characterized by abnormal blood vessel growth in the choroid or retina resul ...

Advanced Vision Therapies, Inc. (AVT) is developing novel therapies for ocular disorders that are the major causes of blindness in the developed world. These diseases include the neovascular ocular disorders, wet age-related macular degeneration (AMD) and diabetic proliferative retinopathy, and the retinal degenerative disorders, retinitis pigmentosa (RP), and dry AMD. AVT has developed a novel le ...

DESCRIPTION (provided by applicant): This Phase I SBIR application is presented by Aeris Therapeutics, Inc. of Woburn, MA. It will examine the feasibility of using a novel enzyme based-system to produce safe, clinically-effective pleurodesis for treatment of malignant pleural effusions. Preliminary data, summarized in this application, suggest that an enzymatic system has the potential for bei ...

DESCRIPTION (provided by applicant): The analysis of components in human breath is a powerful non-invasive technique for the diagnosis and monitoring of asthma, cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). The presence of elevated levels of nitric oxide (NO), carbon monoxide (CO), and ethane (C2H6) in the breath have been identified as biomarkers of these diseases, wh ...

DESCRIPTION (provided by applicant): This Phase I SBIR application addresses the NIAID call for high priority biodefense products such as novel vaccines and therapeutics to protect our nation against various biothreat agents. Although these types of proposals do not require a significant amount of preliminary data, we have already performed substantial preliminary experimental work that encourages ...

DESCRIPTION (provided by applicant): Murine models of cancer now have an essential role in formulating modern concepts of carcinogenesis and metastasis, and provide us with a realistic means of developing and evaluating new diagnostic and therapeutic techniques. Moreover, transgenic and knock-out techniques for manipulating the genome allow us to tailor animal models that accurately recapitulate ...